Short answer
Sana Biotechnology, Inc. (SANA) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$47M
- +4.4% YoY
- EPS (diluted)
- −$0.17
- +19.0% YoY
Source: XBRL data from the Sana Biotechnology, Inc. (SANA) Q1 2026 10-Q on SEC EDGAR. USD.
Sana Biotechnology, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Novel cell-engineering platforms remain unproven, with no FDA-approved PSC-derived or fusogen-based therapeutics
- FDA CAR-T actions include January 2024 class-wide boxed warnings for T-cell malignancies
- Portfolio prioritization suspended two allogeneic CAR-T programs and concentrated development on SC451 and fusogen-enabled programs
- Going-concern uncertainty and need for additional funding threaten continued operations and development
- Foreign licensing arrangements expose operations to currency, tax, political, regulatory, and compliance risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sana Biotechnology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.